AAPL289.85+0.49 (+0.17%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|AAPL289.85+0.49 (+0.17%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|
24.8 C
New York
Wednesday, July 1, 2026

Tag: release

Crypto News Today: AlphaPepe Presale Stage 17 Sold Out as Dogecoin Price Prediction Eyes $1.00

MONACO city, Monaco , June 14, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after the project confirmed that Stage 17 of its presale has sold out and Stage 18 is now live. The presale has raised over $1.55 million, the current token price is $0.01896, and holder growth has climbed above 9,500 as AlphaSwap Early Access, live AI features, and a pending first CEX partnership reveal strengthen the project’s pre-listing profile.

POET DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages POET Technologies Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of POET Technologies Inc. (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, inclusive (the “Class Period”), of the important June 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

ROSEN, THE FIRST FILING FIRM, Encourages Zillow Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.

ENSG Investor News: If You Have Suffered Losses in Ensign Group, Inc. (NASDAQ: ENSG), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

Power Up Winter Adventures: Jackery Australia Launches EOFY Sale with Up to $3,000 Off

Jackery Australia's EOFY Sale offers up to $3,000 off portable power stations and solar generators for winter, running 8 June to 4 July 2026.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages BitGo Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTGO

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of BitGo Holdings, Inc. (NYSE: BTGO): (i) Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with BitGo's January 22, 2026 initial public offering ("IPO"); and/or (ii) securities between January 22, 2026 and May 13, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Author Fari Presents Cambodia’s Path to Peace and Stability in New Book on Hun Sen’s Leadership

ATLANTA, June 14, 2026 (GLOBE NEWSWIRE) -- Author Fari is introducing The Father Who Shielded and Never Left, a book that explores Cambodia's journey toward peace and national development through the leadership experience of Hun Sen, former Prime Minister of Cambodia and current President of the Senate.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRelease